Alnylam Gets Issued U.S. Patent Broadly Covering RNAi Therapeutics - Quick Facts

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/siRNA - Protein Synthesis

Alnylam Gets Issued U.S. Patent Broadly Covering RNAi Therapeutics - Quick Facts
June 06, 2006;
Trading Markets Live!
RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY | charts | news | PowerRating) said that a key fundamental patent from its exclusively held "Tuschl II" patent series was issued by the United States Patent and Trademark Office.
The U.S. patent broadly covers methods of making small interfering RNAs (siRNAs), the molecules that mediate RNAi.
The issued patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Garching Innovation GmbH, the licensing agent for the Max Planck Society.